Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Filings indexed 572 across all filing types
Latest filing 2026-04-21 Share Issue/Capital Cha…
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: New Share Capital
Share Issue/Capital Change Classification · 95% confidence The document is a brief announcement stating that the company’s new share capital has been registered following completion of a private placement. It concerns a change in share capital (number of shares and par value) rather than a full report, earnings release, or management discussion. This fits the definition of a Share Issue/Capital Change announcement (Code SHA).
2026-04-21 English
SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement describing a fresh private placement of equity – subscription of 60,000,000 new shares, the resulting share capital, waiver of preferential rights, and other details of the equity financing. It announces a change in the company’s capital structure via a new share issue. This falls squarely under Share Issue/Capital Change (SHA), rather than general financing (CAP) or any other category.
2026-04-13 English
SoftOx Solutions AS: Fourth Quarter Report 2025 - Attachment: SoftOx Solutions_Q4 Report_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q4 REPORT 2025' and contains comprehensive financial statements, including a Profit and Loss Statement, balance sheet data, and management commentary on business strategy and clinical development. It covers a specific fiscal period (Q4 2025) and provides substantive financial analysis rather than just an announcement or summary. Therefore, it is classified as an Interim/Quarterly Report. Q4 2025
2026-03-25 English
SoftOx Solutions AS: Fourth Quarter Report 2025
Report Publication Announcement Classification · 92% confidence The document is extremely short (178 characters) and only states that the Fourth Quarter Report 2025 is attached, without providing any financial detail or report content. Under the “menu vs meal” rule, this constitutes a report publication announcement rather than the report itself.
2026-03-25 English
SoftOx Solutions AS: New Share Capital
Share Issue/Capital Change Classification · 92% confidence The document announces the completion and registration of a new share capital following a private placement, detailing the updated share capital amount, number of shares, and par value. This is a direct announcement of a capital change through new share issuance. Therefore, it should be classified under Share Issue/Capital Change (SHA).
2026-03-24 English
SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
Capital/Financing Update Classification · 100% confidence The document announces a private placement of shares and the exercise of a financing facility by SoftOx Solutions AS. It details the subscription price, the number of shares issued, the resulting share capital, and the board's justification for waiving shareholders' preferential rights. This falls under the category of capital raising and financing activities, specifically involving the issuance of new shares.
2026-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.